Antitumor effects of Endostar(rh-endostatin) combined with gemcitabine in different administration sequences to treat Lewis lung carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Carnio S, Novello S, Mele T, Levra MG, Scagliotti GV. Extending survival of stage IV non-small cell lung cancer. Semin Oncol. 2014;41(1):69–92. doi:10.1053/j.seminoncol.2013.12.01324565582
   PubMed Web of Science ®Google Scholar
• Cuyun Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res. 2014;6:437–449. doi:10.2147/CMAR.S6360325364274
   PubMed Web of Science ®Google Scholar
• Jung CP, Motwani MV, Schwartz GK. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res. 2001;7(8):2527–2536.11489836
   PubMed Web of Science ®Google Scholar
• Wong P-P, Bodrug N, Hodivala-Dilke KM. Exploring novel methods for modulating tumor blood vessels in cancer treatment. Curr Biol. 2016;26(21):R1161–R1166. doi:10.1016/j.cub.2016.09.04327825457
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis inhibitors generated by tumors. Mol Med. 1995;1(2):120–122.8529090
   PubMed Web of Science ®Google Scholar
• Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer. 2010;10(7):505–514. doi:10.1038/nrc286820574450
   PubMed Web of Science ®Google Scholar
• Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin’s antiangiogenic signaling network. Mol Cell. 2004;13(5):649–663.15023336
   PubMed Web of Science ®Google Scholar
• O’Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277–285.9008168
   PubMed Web of Science ®Google Scholar
• Kim YM, Jang JW, Lee OH, et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res. 2000;60(19):5410–5413.11034081
   PubMed Web of Science ®Google Scholar
• Hanai J, Dhanabal M, Karumanchi SA, et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem. 2002;277(19):16464–16469. doi:10.1074/jbc.M11227420011815623
   PubMed Web of Science ®Google Scholar
• Folkman J. Antiangiogenesis in cancer therapy–endostatin and its mechanisms of action. Exp Cell Res. 2006;312(5):594–607. doi:10.1016/j.yexcr.2005.11.01516376330
   PubMed Web of Science ®Google Scholar
• Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc Res. 1986;31(3):288–305.2423854
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol. 1988;133(1):95–109.2459969
   PubMed Web of Science ®Google Scholar
• Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64(11):3731–3736. doi:10.1158/0008-5472.CAN-04-007415172975
   PubMed Web of Science ®Google Scholar
• Fukumura D, Jain RK. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res. 2007;74(2–3):72–84. doi:10.1016/j.mvr.2007.05.00317560615
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006;3(1):24–40. doi:10.1038/ncponc040316407877
   PubMedGoogle Scholar
• Abraham D, Abri S, Hofmann M, Holtl W, Aharinejad S. Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts. J Urol. 2003;170(4 Pt 1):1388–1393. doi:10.1097/01.ju.0000075917.98929.5714501775
   PubMed Web of Science ®Google Scholar
• Zhu H, Yang X, Ding Y, et al. Recombinant human endostatin enhances the radioresponse in esophageal squamous cell carcinoma by normalizing tumor vasculature and reducing hypoxia. Sci Rep. 2015;5:14503. doi:10.1038/srep1450326412785
   PubMed Web of Science ®Google Scholar
• Ren Z, Wang Y, Jiang W, Dai W, Jiang Y. Anti-tumor effect of a novel soluble recombinant human endostatin: administered as a single agent or in combination with chemotherapy agents in mouse tumor models. PLoS One. 2014;9(9):e107823. doi:10.1371/journal.pone.010782325229620
   PubMed Web of Science ®Google Scholar
• Peng X-C, Qiu M, Wei M, et al. Different combination schedules of gemcitabine with endostar affect antitumor efficacy. Cancer Chemother Pharmacol. 2012;69(1):239–246. doi:10.1007/s00280-011-1695-821706279
   PubMed Web of Science ®Google Scholar
• Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000;60(5):1388–1393.10728704
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539–1544. doi:10.1200/JCO.2006.09.630517442997
   PubMed Web of Science ®Google Scholar
• Ellis LM, Liu W, Ahmad SA, et al. Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin Oncol. 2001;28(5 Suppl 16):94–104.11706401
   PubMed Web of Science ®Google Scholar
• Okines A, Cunningham D. Current perspective: bevacizumab in colorectal cancer – a time for reappraisal? Eur J Cancer. 2009;45(14):2452–2461. doi:10.1016/j.ejca.2009.06.02819643598
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427–434. doi:10.1056/NEJMoa02149112890841
   PubMed Web of Science ®Google Scholar
• Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143–155. doi:10.1016/S1470-2045(13)70586-224411639
   PubMed Web of Science ®Google Scholar
• Zhou S, Yang Y, Yang Y, et al. Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model. PLoS One. 2013;8(7):e68589. doi:10.1371/journal.pone.006858923874680
   PubMed Web of Science ®Google Scholar
• Xu XD, Shao SX, Jiang HP, et al. Warburg effect or reverse Warburg effect? A review of cancer metabolism. Oncol Res Treat. 2015;38(3):117–122. doi:10.1159/00037543525792083
   PubMed Web of Science ®Google Scholar
• Hwang J-A, Lee EH, Kim H-W, Park JB, Jeon BH, Cho C-H. COMP-Ang1 potentiates the antitumor activity of 5-fluorouracil by improving tissue perfusion in murine Lewis lung carcinoma. Mol Cancer Res. 2009;7(12):1920–1927. doi:10.1158/1541-7786.MCR-09-004119952114
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62. doi:10.1126/science.110481915637262
   PubMed Web of Science ®Google Scholar
• Armulik A, Genove G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell. 2011;21(2):193–215. doi:10.1016/j.devcel.2011.07.00121839917
   PubMed Web of Science ®Google Scholar
• Kim KE, Cho C-H, Kim H-Z, Baluk P, McDonald DM, Koh GY. In vivo actions of angiopoietins on quiescent and remodeling blood and lymphatic vessels in mouse airways and skin. Arterioscler Thromb Vasc Biol. 2007;27(3):564–570. doi:10.1161/01.ATV.0000256458.82320.be17194894
   PubMed Web of Science ®Google Scholar
• Matsuo M, Matsumoto S, Mitchell JB, Krishna MC, Camphausen K. Magnetic resonance imaging of the tumor microenvironment in radiotherapy: perfusion, hypoxia, and metabolism. Semin Radiat Oncol. 2014;24(3):210–217. doi:10.1016/j.semradonc.2014.02.00224931096
   PubMed Web of Science ®Google Scholar
• Peng F, Xu Z, Wang J, et al. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PLoS One. 2012;7(4):e34646. doi:10.1371/journal.pone.003464622496834
   PubMed Web of Science ®Google Scholar
• Huang G, Chen L. Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol. 2010;136(8):1201–1211. doi:10.1007/s00432-010-0770-620130910
   PubMed Web of Science ®Google Scholar
• Lev DC, Ruiz M, Mills L, Mcgary EC, Price JE, Bar-Eli M. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther. 2003;2(8):753–763.12939465
   PubMed Web of Science ®Google Scholar
• Riedel F, Gotte K, Goessler U, Sadick H, Hormann K. Targeting chemotherapy-induced VEGF up-regulation by VEGF antisense oligonucleotides in HNSCC cell lines. Anticancer Res. 2004;24(4):2179–2183.15330158
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001;61(8):3369–3372.11309294
   PubMed Web of Science ®Google Scholar
• Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs. 2003;14(1):13–19.12544254
   PubMed Web of Science ®Google Scholar
• Li N, Zheng D, Wei X, Jin Z, Zhang C, Li K. Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model. J Cancer Res Clin Oncol. 2012;138(7):1131–1144. doi:10.1007/s00432-012-1189-z22402599
   PubMed Web of Science ®Google Scholar
• Pauwels B, Korst AE, Pattyn GG, et al. Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int J Radiat Oncol Biol Phys. 2003;57(4):1075–1083.14575839
   PubMed Web of Science ®Google Scholar
• Xu W-J, Huang C, Wang J, et al. Comparison of the effects of recombinant human endostatin and docetaxel on human umbilical vein endothelial cells in different growth states. Chin Med J. 2011;124(18):2883–2889.22040497
   PubMed Web of Science ®Google Scholar
• Fan J, Du J, Wu J, Fu S, Hu D, Wan Q. Antitumor effects of different administration sequences of cisplatin and Endostar on Lewis lung carcinoma. Oncol Lett. 2015;9(2):822–828. doi:10.3892/ol.2014.278325624906
   PubMed Web of Science ®Google Scholar